Invitation-only conference focuses on the evolving landscape of lung cancer risk and early detection when the disease is most treatable bioAffinity Technologies...
Noninvasive diagnostic continues to gain traction in the current and expanding U.S. addressable market of $3.58 billion for pulmonary nodule management and surveillance of lung cancer survivors ...
Panel of leading pulmonologists will share real-world patient cases and benefits of clinical use of the noninvasive CyPath® Lung diagnostic test First...
Panel of leading pulmonologists will share real-world patient cases and benefits of clinical use of the noninvasive CyPath® Lung diagnostic test First...
CyPath® Lung improves diagnostic clarity in patients with multiple lung nodules In this case study, CyPath® Lung “Unlikely Malignancy” result supported...
Laboratory business streamlined in 2025 to focus on profitable diagnostic testing services including the Company’s high-value CyPath® Lung test Number...
Study to evaluate clinical performance of CyPath® Lung for the early detection of lung cancer in high-risk patients Murtha Cancer Center Research Program...
Poster presented to medical and drug industry conferees at prestigious American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting Research...
Validating sample collection by deep suction has potential to accelerate and expand adoption of CyPath® Lung
CyPath® Lung test supported recommendation for surveillance strategy, rather than subjecting elderly patient to an invasive, risky and costly biopsy procedure ...